Detail of "168555-66-6"

Reference

Evaluations of vascular disrupting agents CA4P and OXi4503 in renal cell carcinoma (Caki-1) using a silicon based microvascular casting technique

All Rights Reserved.Some chemicals with cas registry numbers like 288847-35-8 and 168555-66-6 are also used. Evaluations of vascular disrupting agents CA4P and OXi4503 in renal cell carcinoma (Caki-1) using a silicon based microvascular casting technique. Salmon, Howard W.; Mladinich, Christopher; Siemann, Dietmar W. ( Department of Radiation Oncology, Shands Cancer Center at the University of Florida, Gainesville, FL, USA). European Journal of Cancer, 42(17), 3073-3078 (English) 2006 Elsevier Ltd. CODEN: EJCAEL. ISSN: 0959-8049. DOCUMENT TYPE: Journal CA Section: 1 (Pharmacology) The present study evaluated the treatment efficacy of the vascular disrupting agents CA4P and OXi4503 in an orthotopically transplanted human renal cell carcinoma xenograft model (Caki-1). Expts. used vascular casting, vessel d. assessments as well as tumor necrosis measurements to evaluate the efficacy of these agents. After treatment with either agent, assessment of the vascular casts showed an almost total eradication of tumor blood vessels. Histol. evidence further supported this observation, showing extensive central tumor necrosis with only a small viable rim of tumor cells remaining at the periphery. These results suggest that vascular disrupting agents CA4P and OXi4503 may have utility in the treatment of renal cell carcinoma, an encouraging result given that current conventional therapies have been currently largely unsuccessful in managing this disease. .